Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2018-N-2493]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 31 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of August 27, 2018.
 FOR FURTHER INFORMATION CONTACT: Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945, 
                        *Trang.Tran@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. Application No.
Drug
ApplicantANDA 020345
Aminosyn-HF (amino acids) Injection, 8%
ICU Medical, Inc., 600 North Field Dr., Lake Forest, IL 60045.ANDA 040723
Isosorbide Dinitrate Extended-Release Tablets USP, 40 milligrams (mg)
Impax Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544.ANDA 064062
Amphotericin B for Injection USP, 50 mg/vial
Teva Parenteral Medicines, Inc., 19 Hughes, Irvine, CA 92618.ANDA 064200
Cefotaxime for Injection USP, Equivalent to (EQ) 500 mg base/vial, EQ 1 gram (g) base/vial, and EQ 2 g base/vial
Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.( print page 35655)ANDA 064201
Cefotaxime for Injection USP, EQ 10 g base/vial and EQ 20 g base/vial
Do.ANDA 065251
Cefuroxime for Injection USP, EQ 75 g base/bag and EQ 225 g base/bag (Pharmacy Bulk Package)
Samson Medical Technologies, LLC, 2050 Springdale Rd., P.O. Box 2730, Suite 400, Cherry Hill, NJ 08034.ANDA 070892
Metoclopramide Hydrochloride (HCl) Injection, EQ 10 mg base/2 milliliters (mL)
Norbrook Laboratories, Ltd., c/o Norbrook, Inc., 9401 Indian Creek Pkwy., Suite 680, Overland Park, KS 66210.ANDA 075309
Ticlopidine HCl Tablets USP, 250 mg
Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.ANDA 076797
Risperidone Oral Solution USP, 1 mg/mL
Precision Dose, Inc., 722 Progressive Lane, South Beloit, IL 61080.ANDA 077656
Thrive (nicotine polacrilex) Gum USP (Chewable), EQ 4 mg base
GlaxoSmithKline Consumer Healthcare, 184 Liberty Corner Rd., Suite 200, Warren, NJ 07059.ANDA 077658
Thrive (nicotine polacrilex) Gum USP (Chewable), EQ 2 mg base
Do.ANDA 080188
Testosterone Propionate Injection USP, 25 mg/mL, 50 mg/mL, and 100 mg/mL
Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.ANDA 083398
Prednisolone Acetate Injectable Suspension, 25 mg/mL
Do.ANDA 083764
Prednisolone Acetate Injectable Suspension, 50 mg/mL
Do.ANDA 084072
Triamcinolone Diacetate Injection, 40 mg/mL
Do.ANDA 084270
Triamcinolone Tablets USP, 4 mg
Do.ANDA 084466
Reserpine and Hydrochlorothiazide Tablets, 0.125 mg/25 mg
Do.ANDA 084604
Procainamide HCl Capsules, 250 mg
Ivax Pharmaceuticals, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.ANDA 085693
Phentermine HCl Tablets USP, 8 mg
Sandoz, Inc., 4700 Sandoz Dr., Wilson, NC 27893.ANDA 085863
Theophylline Elixir, 80 mg/15 mL
Precision Dose, Inc.ANDA 087185
Ergoloid Mesylates Sublingual Tablets USP, 1 mg
Ivax Pharmaceuticals, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.ANDA 087770
Sulfinpyrazone Capsules USP, 200 mg
Do.ANDA 088648
Methotrexate Injection USP, EQ 25 mg base/mL
Norbrook Laboratories, Ltd., c/o Norbrook, Inc.ANDA 088928
Chlorzoxazone Tablets USP, 250 mg
Actavis Elizabeth, LLC, Subsidiary of Teva Pharmaceuticals USA, Inc.ANDA 090663
Gemcitabine for Injection USP, EQ 200 mg base/vial and EQ 1 g base/vial
Hameln RDS GmbH, c/o B&H Consulting Services, Inc., 50 Division St., Suite 206, Somerville, NJ 08876.ANDA 091469
Vancomycin HCl for Injection USP, EQ 10 g base/vial (Pharmacy Bulk Package)
Mylan Laboratories, Ltd., c/o Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown, WV 26504.ANDA 202390
Tramadol HCl Tablets USP, 50 mg
Accord Healthcare, Inc., 1009 Slater Rd., Suite 210-B, Durham, NC 27703.ANDA 203506
Oxymorphone HCl Extended-Release Tablets, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg
Sun Pharmaceutical Industries, Ltd., c/o Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540.ANDA 204320
Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg
Ajanta Pharma, Ltd., c/o Ajanta Pharma USA, Inc., 440 U.S. Highway 22 East, One Grande Commons, Suite 150, Bridgewater, NJ 08807.ANDA 204706
Olopatadine HCl Ophthalmic Solution USP, EQ 0.1% base
Zambon S.p.A., c/o Camargo Pharmaceutical Services, LLC, 9825 Kenwood Rd., Suite 203, Cincinnati, OH 45242.ANDA 207467
Nevirapine Extended-Release Tablets, 100 mg and 400 mg
Technology Organized, LLC, 9191 Point Replete Dr., Fort Belvoir, VA 22060.
 Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of August 27, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on August 27, 2018 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: July 23, 2018. Leslie Kux, Associate Commissioner for Policy.


[FR Doc. 2018-16037 Filed 7-26-18; 8:45 am] BILLING CODE 4164-01-P